Arcus Biosciences Book Value Per Share Growth & History (RCUS)
Arcus Biosciences's book value per share was $5.04 for fiscal 2025.
View full Arcus Biosciences company overviewArcus Biosciences annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.04 | -$0.22 | −4.27% |
| 2024 | 2024-12-31 | $5.26 | -$0.86 | −14.04% |
| 2023 | 2023-12-31 | $6.12 | -$2.89 | −32.10% |
| 2022 | 2022-12-31 | $9.01 | -$2.88 | −24.22% |
| 2021 | 2021-12-31 | $11.89 | $4.18 | +54.26% |
| 2020 | 2020-12-31 | $7.71 | $4.14 | +115.89% |
| 2019 | 2019-12-31 | $3.57 | -$1.70 | −32.30% |
| 2018 | 2018-12-31 | $5.28 | $22.96 | — |
| 2017 | 2017-12-31 | -$17.68 | -$11.76 | — |
| 2016 | 2016-12-31 | -$5.92 | — | — |
Arcus Biosciences quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.65 | -$1.51 | −29.19% |
| Q1 2026 | 2026-03-31 | $4.18 | -$0.84 | −16.73% |
| Q4 2025 | 2025-12-31 | $5.04 | -$0.22 | −4.27% |
| Q3 2025 | 2025-09-30 | $4.07 | -$2.10 | −34.07% |
| Q2 2025 | 2025-06-30 | $5.16 | -$1.80 | −25.81% |
| Q1 2025 | 2025-03-31 | $5.01 | -$2.76 | −35.53% |
| Q4 2024 | 2024-12-31 | $5.26 | -$0.86 | −14.04% |
| Q3 2024 | 2024-09-30 | $6.17 | -$0.78 | −11.18% |
| Q2 2024 | 2024-06-30 | $6.96 | -$0.64 | −8.45% |
| Q1 2024 | 2024-03-31 | $7.78 | -$0.43 | −5.24% |
| Q4 2023 | 2023-12-31 | $6.12 | -$2.89 | −32.10% |
| Q3 2023 | 2023-09-30 | $6.95 | -$2.71 | −28.04% |
| Q2 2023 | 2023-06-30 | $7.60 | -$2.77 | −26.69% |
| Q1 2023 | 2023-03-31 | $8.21 | -$2.92 | −26.24% |
| Q4 2022 | 2022-12-31 | $9.01 | -$2.88 | −24.22% |
| Q3 2022 | 2022-09-30 | $9.66 | $1.94 | +25.06% |
| Q2 2022 | 2022-06-30 | $10.36 | $1.89 | +22.34% |
| Q1 2022 | 2022-03-31 | $11.13 | $1.76 | +18.79% |
| Q4 2021 | 2021-12-31 | $11.89 | $4.18 | +54.26% |
| Q3 2021 | 2021-09-30 | $7.72 | -$0.66 | −7.88% |
| Q2 2021 | 2021-06-30 | $8.47 | $1.20 | +16.45% |
| Q1 2021 | 2021-03-31 | $9.37 | $6.31 | +206.29% |
| Q4 2020 | 2020-12-31 | $7.71 | $4.14 | +115.89% |
| Q3 2020 | 2020-09-30 | $8.39 | $4.52 | +116.90% |
| Q2 2020 | 2020-06-30 | $7.27 | $2.99 | +69.61% |
| Q1 2020 | 2020-03-31 | $3.06 | -$1.92 | −38.52% |
| Q4 2019 | 2019-12-31 | $3.57 | -$1.70 | −32.30% |
| Q3 2019 | 2019-09-30 | $3.87 | -$1.65 | −29.89% |
| Q2 2019 | 2019-06-30 | $4.29 | -$1.44 | −25.11% |
| Q1 2019 | 2019-03-31 | $4.98 | -$1.02 | −17.04% |
| Q4 2018 | 2018-12-31 | $5.28 | $22.96 | — |
| Q3 2018 | 2018-09-30 | $5.51 | — | — |
| Q2 2018 | 2018-06-30 | $5.73 | — | — |
| Q1 2018 | 2018-03-31 | $6.00 | — | — |
| Q4 2017 | 2017-12-31 | -$17.68 | — | — |
Arcus Biosciences book value per share trends
Over the last five fiscal years, Arcus Biosciences's book value per share decreased from $7.71 to $5.04, a change of -$2.67. The latest reported quarter, Q2 2026, shows $3.65.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcus Biosciences source filings ↗